Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(abciximab)
2,774 results
  • An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives. [Review]
    High Blood Press Cardiovasc Prev. 2023 Jan 13 [Online ahead of print]Sharifi-Rad J, Sharopov F, … Calina D
  • The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation through the competition with fibrinogen and von Willebrand factor. Currently, three parenteral GP IIb/IIIa competitors (tirofiban, eptifibatide, and abciximab) are approved for clinical use in patients aff…
  • Targeting integrin pathways: mechanisms and advances in therapy. [Review]
    Signal Transduct Target Ther. 2023 Jan 02; 8(1):1.Pang X, He X, … Cui Y
  • Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mec…
  • GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect. [Journal Article]
    Mol Pharm. 2023 Jan 02; 20(1):663-679.Priya V, Singh SK, … Muthu MS
  • Rutin (RUT) is a flavonoid obtained from a natural source and is reported for antithrombotic potential, but its delivery remains challenging because of its poor solubility and bioavailability. In this research, we have fabricated novel rutin loaded liposomes (RUT-LIPO, nontargeted), liposomes conjugated with RGD peptide (RGD-RUT-LIPO, targeted), and abciximab (ABX-RUT-LIPO, targeted) by ethanol i…
  • Anti-platelet peptides targeting αIIbβ3 outside-in signaling pathway [Journal Article]
    Curr Protein Pept Sci. 2022 11 14 [Online ahead of print]Wang J, Xu X
  • Platelets and their progenitors express high levels of integrin αIIbβ3, which plays a key role in platelet functions, hemostasis, and arterial thrombosis. Because of their quick and high efficacy, the three anti-αIIbβ3 drugs, abciximab, eptifibatide, and tirofiban, are regarded as potent anti-thrombotics and clinically approved by US Food and Drug Administration. However, because they interfere w…
  • It's the water! The open and shut case of drug-induced integrin activation. [Comment]
    Cell. 2022 09 15; 185(19):3463-3466.Coller BS
  • Integrin receptors are established drug targets, but many of the drugs that have been developed act as partial agonists, inducing the receptor into a high-affinity, ligand-binding state. Lin et al. discovered a general mechanism to circumvent this problem-stabilizing a key water molecule that prevents receptor activation. Their findings are likely to impact future therapeutic development.
  • StatPearls: Abciximab [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)Stoffer K, Bistas KG, … Shah SBOOK
  • Researchers have studied abciximab in three-phase III clinical trials: EPIC, EPILOG, and CAPTURE. Abciximab is no longer manufactured.
  • Drugs and Lactation Database (LactMed): Abciximab [BOOK]
    Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
  • No information is available on the clinical use of abciximab during breastfeeding. Because abciximab is a large protein molecule with a molecular weight of 47,615 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, abciximab should be used with caution during breastfee…
  • Antiplatelet agents for chronic kidney disease. [Review]
    Cochrane Database Syst Rev. 2022 02 28; 2:CD008834.Natale P, Palmer SC, … Strippoli GF
  • CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.
  • A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. [Journal Article]
    World J Pharm Pharm Sci. 2021 Nov; 10(11):14-22.Puthenpurail A, Rathi H, … Ally A
  • Monoclonal antibodies (mAbs) are increasingly being prescribed to patients and investigated in the field of medicine and research. This class of medication is unique due to its ability to be engineered into targeting a specific receptor. Numerous studies and reviews have reported the efficacy, potency, and clinical usage of mAbs in the treatment of a variety of diseases ranging from autoimmune di…
  • Ruptured Proximal Anterior Cerebral Artery Aneurysm Treated with Flow Diverter. [Case Reports]
    Turk Neurosurg. 2022; 32(1):160-165.Giorgianni A, Vinacci G, … Locatelli D
  • CONCLUSIONS: A1 aneurysm endovascular treatment is often challenging. Coiling or assisted coiling is the most frequently employed. Although flow diverter stent (FDS) is a consolidated technique for treating ruptured intracranial blister-like and dissecting aneurysms, its role in treating intracranial saccular ruptured aneurysms has to be elucidated. However, more number of case studies is needed to confirm the efficacy and safety of an FDS in treating ruptured A1 aneurysms.
  • Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms. [Multicenter Study]
    J Pediatr. 2022 01; 240:164-170.e1.Selamet Tierney ES, Runeckles K, … International Kawasaki Disease Registry
  • CONCLUSIONS: In the IKDR, IVIG and ASA therapy as primary therapy is universal with common use of a second dose of IVIG for persistent fever. There is practice variation among centers for adjunctive therapies and anticoagulation strategies, likely reflecting ongoing knowledge gaps. Randomized controlled trials nested in a high-quality collaborative registry may be an efficient strategy to reduce practice variation.
  • Lysis of arterial thrombi by perfusion of N,N'-Diacetyl-L-cystine (DiNAC). [Journal Article]
    PLoS One. 2021; 16(2):e0247496.Kim D, Shea SM, Ku DN
  • The search persists for a safe and effective agent to lyse arterial thrombi in the event of acute heart attacks or strokes due to thrombotic occlusion. The culpable thrombi are composed either primarily of platelets and von Willebrand Factor (VWF), or polymerized fibrin, depending on the mechanism of formation. Current thrombolytics were designed to target red fibrin-rich clots, but may be not be…
New Search Next